Physician profile
Ira M Fine
NPI 1235166851
$854.16
in general payments reported to CMS, 2019-2025
16 companies · $59.44 in 2025
The $59.44 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $329 · 2021: $215 · 2022: $28.28 · 2023: $28.03 · 2024: $51.43 · 2025: $59.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $138.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $181.86 | 2020-2022 | |
| Astellas Pharma US INC | $177.79 | 2019-2021 | |
| Allergan, INC. | $95.24 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $85.24 | 2021-2025 | Acthar |
| Abbvie INC. | $81.03 | 2021-2023 | |
| Eisai INC. | $32.62 | 2021 | |
| Corcept Therapeutics | $32.08 | 2025 | Korlym |
| Pfizer INC. | $28.43 | 2020 | |
| Amneal Pharmaceuticals LLC | $26.36 | 2020 | |
| Advanced Respiratory, INC | $19.19 | 2020 | |
| Janssen Pharmaceuticals, INC | $18.75 | 2020 | |
| Mylan Specialty L.P. | $18.71 | 2021 | |
| Lilly USA, LLC | $17.12 | 2024 | Zepbound, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $13.85 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.76 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $12.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Fine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.